136 related articles for article (PubMed ID: 19066894)
21. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
[TBL] [Abstract][Full Text] [Related]
23. Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort.
Pernot S; Mitry E; Samalin E; Dahan L; Dalban C; Ychou M; Seitz JF; Turki H; Mazard T; Zaanan A; Lepère C; Vaillant JN; Landi B; Rougier P; Taieb J
Gastric Cancer; 2014 Apr; 17(2):341-7. PubMed ID: 23739764
[TBL] [Abstract][Full Text] [Related]
24. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).
Wöll E; Greil R; Eisterer W; Bechter O; Fridrik MA; Grünberger B; Zabernigg A; Mayrbäurl B; Russ G; Dlaska M; Obrist P; Thaler J
Anticancer Res; 2011 Dec; 31(12):4439-43. PubMed ID: 22199312
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of docetaxel, cisplatin and concurrent radiotherapy for locally advanced gastric adenocarcinoma.
Xing L; Lu H; Zhang J; Yu J; Wang F; Yu X; Yu H; Xia L
Neoplasma; 2012; 59(4):370-5. PubMed ID: 22489691
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.
Moehler M; Mahlberg R; Heinemann V; Obermannová R; Kubala E; Melichar B; Weinmann A; Scigalla P; Tesařová M; Janda P; Hédouin-Biville F; Mansoor W
Gastric Cancer; 2017 Mar; 20(2):358-367. PubMed ID: 27255289
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer.
Quintero-Aldana G; Jorge M; Grande C; Salgado M; Gallardo E; Varela S; López C; Villanueva MJ; Fernández A; Alvarez E; González P; Castellanos J; Casal J; López R; Campos Balea B
Cancer Chemother Pharmacol; 2015 Oct; 76(4):731-7. PubMed ID: 26242221
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001.
Hejna M; Raderer M; Zacherl J; Ba-Ssalamah A; Püspök A; Schmidinger M; Pluschnig U; Brodowicz T; Zielinski CC
Anticancer Drugs; 2008 Jun; 19(5):535-9. PubMed ID: 18418220
[TBL] [Abstract][Full Text] [Related]
29. Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
Lim JY; Cho JY; Paik YH; Lee DK; Lee SI; Park HJ; Lee SJ; Lee KS; Yoon DS; Choi SH
Oncology; 2007; 73(1-2):2-8. PubMed ID: 18332648
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.
Lee JL; Ryu MH; Chang HM; Kim TW; Yook JH; Oh ST; Kim BS; Kim M; Chun YJ; Lee JS; Kang YK
Cancer Chemother Pharmacol; 2008 Apr; 61(4):631-7. PubMed ID: 17520252
[TBL] [Abstract][Full Text] [Related]
31. A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial.
Chen MH; Lin J; Hsiao CF; Shan YS; Chen YC; Chen LT; Liu TW; Li CP; Chao Y
Medicine (Baltimore); 2016 Jan; 95(3):e2565. PubMed ID: 26817912
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II Study of S-1 Plus Cisplatin Alternating With S-1 Plus Docetaxel in Patients With Advanced Gastric Cancer.
Hosokawa A; Ando T; Ogawa K; Ueda A; Yoshita H; Mihara H; Fujinami H; Kajiura S; Yabushita K; Horikawa N; Kobayashi Y; Yoshioka A; Origasa H; Sugiyama T
Am J Clin Oncol; 2018 Oct; 41(10):977-981. PubMed ID: 28930775
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Hironaka S; Yamazaki K; Taku K; Yokota T; Shitara K; Kojima T; Ueda S; Machida N; Muro K; Boku N
Jpn J Clin Oncol; 2010 Nov; 40(11):1014-20. PubMed ID: 20603245
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction.
Richards D; McCollum D; Wilfong L; Sborov M; Boehm KA; Zhan F; Asmar L
Ann Oncol; 2008 Jan; 19(1):104-8. PubMed ID: 17897959
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
36. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
[TBL] [Abstract][Full Text] [Related]
37. Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age.
Zang DY; Yang DH; Lee HW; Hwang SW; Song HH; Jung JY; Kwon JH; Kim HJ; Kim JH; Park SR; Kim MJ; Jang KM; Park CK; Kim JH; Lee BH
Cancer Chemother Pharmacol; 2009 Feb; 63(3):509-16. PubMed ID: 18481067
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
Meulendijks D; de Groot JW; Los M; Boers JE; Beerepoot LV; Polee MB; Beeker A; Portielje JE; Goey SH; de Jong RS; Vanhoutvin SA; Kuiper M; Sikorska K; Pluim D; Beijnen JH; Schellens JH; Grootscholten C; Tesselaar ME; Cats A
Cancer; 2016 May; 122(9):1434-43. PubMed ID: 26970343
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.
El-Rayes BF; Zalupski M; Bekai-Saab T; Heilbrun LK; Hammad N; Patel B; Urba S; Shields AF; Vaishampayan U; Dawson S; Almhanna K; Smith D; Philip PA
Ann Oncol; 2010 Oct; 21(10):1999-2004. PubMed ID: 20332133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]